| A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation Z Yu, C Wang, M Wang, Z Li, MC Casimiro, M Liu, K Wu, J Whittle, X Ju, ... The Journal of cell biology 182 (3), 509-517, 2008 | 455 | 2008 |
| Patient-derived xenograft models of breast cancer and their predictive power JR Whittle, MT Lewis, GJ Lindeman, JE Visvader Breast cancer research 17, 1-13, 2015 | 328 | 2015 |
| Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer D Merino, JR Whittle, F Vaillant, S Antonin, JN Gong, G Giner, ... Science Translational Medicine 9 (401), 2017 | 183 | 2017 |
| Modeling breast cancer using CRISPR-Cas9–mediated engineering of human breast organoids JF Dekkers, JR Whittle, F Vaillant, HR Chen, C Dawson, K Liu, MH Geurts, ... JNCI: Journal of the National Cancer Institute 112 (5), 540-544, 2020 | 150 | 2020 |
| A phase Ib dose-escalation and expansion study of the BCL2 inhibitor venetoclax combined with tamoxifen in ER and BCL2–positive metastatic breast cancer SW Lok, JR Whittle, F Vaillant, CE Teh, LL Lo, AN Policheni, ART Bergin, ... Cancer discovery 9 (3), 354-369, 2019 | 135 | 2019 |
| First in human nanotechnology doxorubicin delivery system to target epidermal growth factor receptors in recurrent glioblastoma JR Whittle, JD Lickliter, HK Gan, AM Scott, J Simes, BJ Solomon, ... Journal of Clinical Neuroscience 22 (12), 1889-1894, 2015 | 114 | 2015 |
| Dual targeting of CDK4/6 and BCL2 pathways augments tumor response in estrogen receptor–positive breast cancer JR Whittle, F Vaillant, E Surgenor, AN Policheni, G Giner, BD Capaldo, ... Clinical Cancer Research 26 (15), 4120-4134, 2020 | 83 | 2020 |
| Sirtuins, nuclear hormone receptor acetylation and transcriptional regulation JR Whittle, MJ Powell, VM Popov, LA Shirley, C Wang, RG Pestell Trends in Endocrinology & Metabolism 18 (9), 356-364, 2007 | 66 | 2007 |
| Targeting triple-negative breast cancers with the Smac-mimetic birinapant N Lalaoui, D Merino, G Giner, F Vaillant, D Chau, L Liu, T Kratina, B Pal, ... Cell Death & Differentiation 27 (10), 2768-2780, 2020 | 40 | 2020 |
| A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers A Roohullah, A Cooper, AJ Lomax, J Aung, A Barge, L Chow, M McHale, ... Investigational new drugs 36, 886-894, 2018 | 29 | 2018 |
| Histone deacetylase inhibitors in cancer: What have we learned? JR Whittle, J Desai Cancer 121 (8), 1164-1167, 2015 | 16 | 2015 |
| Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancer S Sharma, CY Chung, S Uryu, J Petrovic, J Cao, A Rickard, N Nady, ... Cell Chemical Biology 30 (10), 1191-1210. e20, 2023 | 14 | 2023 |
| PALVEN: phase Ib trial of palbociclib, letrozole and venetoclax in estrogen receptor-and BCL2-positive advanced breast cancer C Muttiah, JR Whittle, C Oakman, GJ Lindeman Future Oncology 18 (15), 1805-1816, 2022 | 14 | 2022 |
| Carboplatin dosing in the era of IDMS-creatinine; the Cockroft-Gault formula no longer provides a sufficiently accurate estimate of glomerular filtration rate for routine use … L McLean, JR Whittle, J Graham, H Ismail, M Lichtenstein, RJ Hicks, ... Gynecologic Oncology 157 (3), 793-798, 2020 | 14 | 2020 |
| First-in-class KAT6A/KAT6B inhibitor CTx-648 (PF-9363) demonstrates potent anti-tumor activity in ER+ breast cancer with KAT6A dysregulation S Sharma, J Chung, S Uryu Cancer Res. 81 (Suppl. 13), 1130-1130, 2021 | 13 | 2021 |
| Safety and efficacy of the BCL2 inhibitor venetoclax in estrogen receptor (ER) and BCL2-positive metastatic breast cancer: The mBEP study. GJ Lindeman, SW Lok, AR Bergin, JR Whittle, K Shackleton, P Sherman, ... Journal of Clinical Oncology 35 (15_suppl), 1044-1044, 2017 | 11 | 2017 |
| Correlating MRI features with additional genetic markers and patient survival in histological grade 2-3 IDH-mutant astrocytomas A Lasocki, ME Buckland, T Molinaro, J Xie, JR Whittle, H Wei, F Gaillard Neuroradiology 65 (8), 1215-1223, 2023 | 10 | 2023 |
| Spatial architecture of high-grade glioma reveals tumor heterogeneity within distinct domains JJD Moffet, OE Fatunla, L Freytag, J Kriel, JJ Jones, SJ Roberts-Thomson, ... Neuro-Oncology Advances 5 (1), vdad142, 2023 | 10 | 2023 |
| In vivo genome‐editing screen identifies tumor suppressor genes that cooperate with Trp53 loss during mammary tumorigenesis L Heitink, JR Whittle, F Vaillant, BD Capaldo, JF Dekkers, CA Dawson, ... Molecular Oncology 16 (5), 1119-1131, 2022 | 10 | 2022 |
| Moderately hypofractionated versus conventionally fractionated radiation therapy with temozolomide for young and fit patients with glioblastoma: an institutional experience and … P Chidley, M Shanker, C Phillips, N Haghighi, MB Pinkham, JR Whittle, ... Journal of neuro-oncology 160 (2), 361-374, 2022 | 7 | 2022 |
